Background Ivermectin, an antiparasitic agent used to treat parasitic infestations, inhibits the
replication of viruses in vitro. The molecular hypothesis of ivermectin's antiviral mode of …

Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …

Background Monoclonal antibodies (mAbs) are laboratory‐produced molecules derived
from the B cells of an infected host. They are being investigated as a potential therapy for …

Background Indications for the use of negative pressure wound therapy (NPWT) are broad
and include prophylaxis for surgical site infections (SSIs). Existing evidence for the …

Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …

Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …

Objectives To compare the time to treatment failure, remission and first seizure of 12 AEDs
(carbamazepine, phenytoin, sodium valproate, phenobarbitone, oxcarbazepine, lamotrigine …

Background Resilience can be defined as the maintenance or quick recovery of mental
health during or after periods of stressor exposure, which may result from a potentially …

Background Ventilator‐associated pneumonia (VAP) is defined as pneumonia developing in
people who have received mechanical ventilation for at least 48 hours. VAP is a potentially …

Background Medication‐related osteonecrosis of the jaw (MRONJ) is a severe adverse
reaction experienced by some individuals to certain medicines commonly used in the …